From Valley of Despair to FDA Threshold: The Turnaround of COMPASS Pathways (CMPS)
Investing.com reports COMPASS Pathways (CMPS) trades at $13.45 as of Aug 14, 2026, up 211% over 12 months. The company is pursuing an FDA NDA for COMP360 for treatment-resistant depression, targeting completion in Q4 2026 and review in 2027. It cites Phase 3 results (p<0.001) and $433M cash as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The text frames a probability shift from long regulatory uncertainty to a defined decision path: rolling NDA review underway, Q4 2026 completion target, and potential FDA decision in early 2027, contingent on DEA rescheduling and REMS readiness.
Market read
This is a forward-looking regulatory and commercialization roadmap for CMPS, emphasizing the next 5 to 9 months as the key window for approval probability and launch feasibility.
What to watch
The article flags a shelf registration and cash runway, but traders should also monitor NDA module review progress, REMS operational timelines at interventional psychiatry centers, and any changes in regulatory expectations for psychedelic therapies.
Background
CMPS is developing COMP360 (synthetic psilocybin) for treatment-resistant depression, with a history of adverse-event concerns in earlier dosing and later Phase 3 success.
Ticker impact
COMPASS Pathways (CMPS) is advancing its rolling NDA for COMP360, targeting Q4 2026 completion and potential FDA approval in early 2027.
Bullish bias into Q4 2026 NDA milestones, but high volatility risk around any regulatory slippage or dilution signals.
The article provides a concrete regulatory timeline (rolling NDA, Q4 2026 completion, possible Q1 to Q2 2027 approval) plus key gating items (DEA rescheduling, REMS finalization) that can reprice probability of approval and launch readiness.
Market effects
If CMPS clears FDA and DEA hurdles, it strengthens the probability-weighted path for other psychedelic TRD programs and may lift sector sentiment.
Limited direct regional spillover; primary impact is US regulatory pathway and US clinical/launch infrastructure.
US FDA and DEA decisions set a global precedent for psychedelic therapeutics commercialization and regulatory expectations.
Counterpoint
Even with positive Phase 3 results, launch economics can be delayed or impaired if DEA rescheduling and REMS certification lag the FDA approval timeline.
Key entities
- drug_programCOMP360
Synthetic psilocybin therapy candidate for treatment-resistant depression, the subject of the NDA and regulatory gating items.
- regulatory_toolFDA Priority Review Voucher
A voucher that can compress review to as little as one to two months post-NDA submission, potentially pulling the PDUFA earlier.
- regulatory_gateDEA rescheduling
Required to move psilocybin off Schedule I to enable commercial distribution after FDA approval.
- regulatory_safety_programREMS
A structured safety program the FDA will likely impose, requiring certification and operational readiness.
- clinical_collaborationPIVOT trial
Collaboration with the US Department of Veterans Affairs to study COMP360 in veterans with TRD and concurrent PTSD.
